Short Blogs

Learn when N-of-1 trials require ethics approval and explore the key factors that distinguish routine clinical care from research, including a practical framework to support ethical decision-making.

Rare diseases demand new ways of generating evidence. Learn how the Emma Center for Personalized Medicine is using single-case experimental designs and N-of-1 trials to accelerate the development, evaluation and implementation of personalised therapies.

How can physiotherapists determine what works best for an individual patient? This article explores how single-case experimental designs can support evidence-informed, patient-centred care and highlights key recommendations for designing and reporting rigorous SCEDs.

Single-case experimental designs took centre stage at the 12th European Pain Federation (EFIC) Congress, highlighting their growing role in chronic pain research and personalised care. Read the key highlights.

As healthcare becomes increasingly personalised, digital technologies and N-of-1 approaches are reshaping how individuals manage their health. Explore the future of precision medicine and patient-centred care.

Discover how single-case designs can strengthen complementary and alternative medicine research by supporting personalised care while addressing challenges such as slow treatment effects and washout periods.

Authors: Maria Depenweiller, Kathryn Moseley, Kirsten Ahring, Ash Morgan Chambers & Annie Prince In phenylketonuria (PKU), a rare condition, deficient metabolism of phenylalanine to tyrosine disrupts blood-to brain transport of large neutral amino acids (LNAAs). LNAAs compete for brain influx, dependent on blood concentrations which can be manipulated by diet. Higher blood phenylalanine in PKU produces excessive brain entry at the expense of tyrosine and other LNAAs. Without

Authors: Anne MacGregor & Alec Mian We can easily recognize the face of someone we know from thousands if not millions of other humans....

N-of-1 trials are one of the few research methods that can determine whether a treatment works for an individual. Discover why they have a broader role in personalised medicine than is often recognised.

Authors: Jane Nikles, Eric J. Daza, Suzanne McDonald, Eric Hekler and Nicholas Schork The number of published N-of-1 articles has doubled...

Dr Joanne Bradbury and Professor Sandra Grace discuss a training program for complementary medicine practitioners

Describes progress towards priorities for the ICN

Authors: Kenneth Shulman, Amparo Casanova & Marina Vives-Metres

Authors: Samuel Tan, Farhad Fatehi, Steve Donoghue and Sandy Bodner

Authors: Dr Joanne Bradbury, Prof Sandra Grace and Dr Cathy Avila A system of healthcare that does not recognise traditional...

Authors: Dr James McGree and Samuel Tan Progress towards a global rare disease registry An MTPConnect funded project is currently...

Author: Dr Veronique Chachay As a key component of evidence-based healthcare, nutrition research provides insight into a number of...

Authors: Dr Carrie Ritchie, Dr Kelly Clanchy, Dr Sean Tweedy, Dr Melissa Day, A/Prof. Jane Nikles, Prof. Robyn Tate, Prof. Michele...

Study in progress! Authors: Dr Jane Nikles, A/Prof. John O’Sullivan, Prof. Geoff Mitchell, Dr Alex Ritchie, A/Prof. Simon Smith, Dr Hugh...

Full title: Effect of mexiletine on muscle stiffness in patients with nondystrophic myotonia evaluated using aggregated N-of-1 trials: a...

Author: Dr Suzanne McDonald Single-case (or ‘N-of-1’) methodology provides researchers and clinicians with a flexible and rigorous...

Authors: Dr Jane Nikles and Sherin Jacob Study summary WORK IN PROGRESS! We are applying Bayesian modelling of prior data for a...

I’m James McGree, an Associate Professor of Statistics at the Queensland University of Technology, Brisbane, Australia and the ICN...

Author: Samuel Tan Randomized controlled trials (RCTs) first rose to prominence in the mid-20th century, heralded as a systematic, rigorous and efficient alternative to case studies and physician testimonials. The initial breakthroughs were numerous – streptomycin for pulmonary tuberculosis, heparin for atherosclerosis – and RCTs rapidly grew to their current position as the pre-eminent study design in medicine. Nonetheless, RCTs are not without their weaknesses, many of whic